Larsson, B. A. M.
Johansson, L.
Johansson, H.
Axelsson, K. F.
Harvey, N.
Vandenput, L.
Magnusson, P.
McCloskey, E.
Liu, E.
Kanis, J. A.
Sundh, D.
Lorentzon, M. http://orcid.org/0000-0003-0749-1431
Funding for this research was provided by:
Sahlgrenska Universitetssjukhuset
Vetenskapsrådet
IngaBritt och Arne Lundbergs Forskningsstiftelse
Article History
Received: 17 June 2020
Accepted: 9 October 2020
First Online: 21 October 2020
Compliance with ethical standards
: All subjects signed an informed consent, prior to participation. The study protocol has been approved by the regional Ethics Review Board in Gothenburg.
: Professor Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. J. A. Kanis has received grant support from Amgen, Lilly, and Radius Health; N. Harvey has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health, and Internis Pharma outside the scope of the submitted work. K. Axelsson has received lecture fees from Lilly, Meda/Mylan, and Amgen. E. McCloskey has received research funding, consultancy, lecture fees, and/or honoraria from Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, UCB, Unilever, and Warner Chilcott.